Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early LT4 Replacement After Radioiodine for Graves' Disease
NCT01295333Phase 3Completed
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- May 2011
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of levothyroxine sodium in Graves' disease (2 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Quality of Life (ThyPRO) at 3 months. Started May 2011; status: completed.
02
Drugs
levothyroxine sodium
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT01295333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01295333.